The estimated Net Worth of Andrew J Grethlein is at least $5.06 Миллион dollars as of 8 July 2024. Andrew Grethlein owns over 674,348 units of Geron stock worth over $2,960,388 and over the last 12 years he sold GERN stock worth over $1,165,699. In addition, he makes $930,994 as Executive Vice President и Chief Operating Officer at Geron.
Sign up
Andrew Grethlein GERN stock SEC Form 4 insiders trading
Andrew has made over 3 trades of the Geron stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 674,348 units of GERN stock worth $1,159,879 on 8 July 2024.
The largest trade he's ever made was exercising 674,348 units of Geron stock on 8 July 2024 worth over $1,159,879. On average, Andrew trades about 71,877 units every 37 days since 2013. As of 8 July 2024 he still owns at least 674,348 units of Geron stock.
You can see the complete history of Andrew Grethlein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Grethlein biography
Dr. Andrew J. Grethlein Ph.D. serves as Executive Vice President, Chief Operating Officer of the Company. Previously, he served as our Executive Vice President, Development and Technical Operations, from July 2014 to January 2019. He joined Geron in September 2012 as our Executive Vice President, Technical Operations. Prior to joining Geron, Dr. Grethlein was Executive Vice President and Chief Operating Officer for Inspiration Biopharmaceuticals, a biopharmaceutical company, from January 2010 to September 2012. From October 2008 until January 2010, Dr. Grethlein was Senior Vice President of Biotechnology and Portfolio Management Team Leader for Hematology at Ipsen S.A., a global specialty pharmaceutical company. His responsibilities at Ipsen included planning and execution of worldwide strategy for product and portfolio development in the hematologic therapeutic area. From 2003 to 2008, Dr. Grethlein served as Senior Vice President of Pharmaceutical Operations at Tercica, Inc., an endocrinology-oriented biopharmaceutical company, where he was a member of the senior executive team that governed corporate strategy, business planning and company operations, and had responsibility for all manufacturing and quality functions. Before joining Tercica, Dr. Grethlein served in various positions at Elan Corporation, a biotechnology company, from 1997 to 2003, including as Senior Director, South San Francisco Pharmaceutical Operations. From 1995 to 1997, Dr. Grethlein served as Manager, Biologics Development and Manufacturing, for Athena Neurosciences, Inc., a pharmaceutical company. Prior to this, he served in various engineering positions for the Michigan Biotechnology Institute, a nonprofit technology research and business development corporation. Dr. Grethlein received his A.A. degree in liberal arts from Simon’s Rock Early College, his B.S. in biology from Bates College, and his M.S. and Ph.D. in chemical engineering from Michigan State University.
What is the salary of Andrew Grethlein?
As the Executive Vice President и Chief Operating Officer of Geron, the total compensation of Andrew Grethlein at Geron is $930,994. There are 4 executives at Geron getting paid more, with John Scarlett having the highest compensation of $1,941,140.
How old is Andrew Grethlein?
Andrew Grethlein is 55, he's been the Executive Vice President и Chief Operating Officer of Geron since 2019. There are 12 older and 7 younger executives at Geron. The oldest executive at Geron Corp. is Stephen N. Rosenfield, 71, who is the Exec. VP, Chief Legal Officer & Corp. Sec..
What's Andrew Grethlein's mailing address?
Andrew's mailing address filed with the SEC is C/O GERON CORPORATION, 919 E. HILLSDALE BLVD, SUITE 250, FOSTER CITY, CA, 94404.
Insiders trading at Geron
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury и Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
What does Geron do?
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
What does Geron's logo look like?
Complete history of Andrew Grethlein stock trades at Geron
Geron executives and stock owners
Geron executives and other stock owners filed with the SEC include:
-
John Scarlett,
Chairman of the Board, President, Chief Executive Officer -
Aleksandra Rizo,
Executive Vice President, Chief Medical Officer -
Dr. John A. Scarlett,
CEO, Pres & Chairman -
Stephen Rosenfield,
Executive Vice President, Corporate Secretary, Chief Legal Officer -
Andrew Grethlein,
Executive Vice President, Chief Operating Officer -
Olivia Bloom,
Chief Financial Officer, Executive Vice President - Finance, Treasurer -
Melissa Kelly Behrs,
Executive Vice President, Chief Business Officer -
Dr. Aleksandra Rizo M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Dr. Andrew J. Grethlein,
Exec. VP & COO -
Melissa A. Kelly Behrs,
Exec. VP of Bus. Operations & Chief Alliance Officer -
Olivia Kyusuk Bloom,
Exec. VP of Fin., CFO & Treasurer -
Elizabeth O'Farrell,
Independent Director -
Dawn Bir,
Independent Director -
Karin Eastham,
Lead Independent Director -
V. Bryan Lawlis,
Independent Director -
Robert Spiegel,
Independent Director -
Susan Molineaux,
Independent Director -
Anil Kapur,
Executive Vice President, Corporate Strategy and Chief Commercial Officer -
Edward E. Koval,
Exec. VP & Chief Bus. Officer -
Anil Kapur,
Chief Commercial Officer & Exec. VP of Corp. Strategy -
Stephen N. Rosenfield,
Exec. VP, Chief Legal Officer & Corp. Sec. -
Shannon Odam,
VP of HR -
Suzanne Messere,
Head of Investor Relations & Corp. Communications -
Daniel Bradbury,
Director -
Thomas Hofstaetter,
Director -
Hoyoung Huh,
Director -
James Ziegler,
EVP, Chief Commercial Officer -
Gaurav Aggarwal,
-
Calvin Harley,
Chief Scientific Officer -
Graham K Cooper,
EVP, Bus Dev & CFO -
Katharine E. Spink,
VP Operations, Regen Med Progs -
Jane Lebkowski,
VP Regenerative Medicine -
David Greenwood,
SVP Corporate Development and -
Melanie I Nallicheri,
SVP Corp Dev -
Alexander E Barkas,
Director -
Charles J Homcy,
Director -
Thomas Okarma,
President and CEO -
Patrick J Zenner,
Director -
Fabio M Benedetti,
SVP, Chief Med Off, Oncology -
John Peter Walker,
Director -
Alan Colowick,
President, Oncology -
Robert B Stein,
Director -
Stephen Michael Kelsey,
EVP, CMO, Oncology -
Edward V Fritzky,
Director -
Craig C Parker,
SVP, Corporate Development -
David Earp,
VP Intellectual Property -
Thomas Kiley,
Director -
Bioscience Inc Merix,
10% owner -
William Stempel,
VP and General Counsel -
John F Mc Donald,
-
Faye Feller,
EVP, Chief Medical Officer -
Scott Alan Samuels,
EVP, Chief Legal Officer -
Michelle Robertson,
EVP, Chief Financial Officer